clinical trial · NCT07234591
A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
Plaque PsoriasisModerate to Severe Plaque PsoriasisTyk2 inhibitorPlacebo
brief summary
A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
started
Oct 21, 2025
primary completion
Apr 30, 2026
completion
May 30, 2026
last updated
Nov 18, 2025
official title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol